About Biomatics Capital
Biomatics Capital is a venture capital firm founded in 2016. It is primarily based out of Seattle, United States. As of Jan 2021, Biomatics Capital has invested in 19 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series C round of Encodia Overall, Biomatics Capital portfolio has seen 1 unicorn, 6 IPOs and 5 acquisitions including key companies like Aledade, Denali Therapeutics and Twist Bioscience. A lot of funds co-invest with Biomatics Capital, with names like Arch Venture Partners sharing a substantial percentage of its portfolio. Biomatics Capital has team of 2 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 3 more
Portfolio Unicorns
Portfolio Soonicorns
Biomatics Capital's List of Top Investments
Biomatics Capital has a portfolio of 19 companies, one of which is a Unicorn. Their most notable investments are in Encodia and Aledade.Their portfolio spans across United States and China. They have invested in Life Sciences, High Tech, Enterprise Applications and 2 other sectors, across stages such as Series A, Series B and 3 more. Here is the list of top investments by Biomatics Capital:1. Aledade
Provider of primary care physician platform to deliver care for patients. The platform offers data analytics, guided workflows, healthcare policy expertise, and payer relationships for independent practices health centers, and clinics. It helps practioners and health centers optimize patient outcomes and generate revenue through value based care.
Key facts about Aledade
- Founded Year: 2014
- Location: Bethesda (United States)
- Valuation: $*****
- Stage: Series F
- Total Funding till date: $780M
- Employee Count: 1,936 as on Jul 31, 2026
- Investors: Meritech, Section Partners and 18 Others
- Latest Funding Round: Conventional Debt, Dec 02, 2025, $*****
- Highlight: Editors' Pick
Developer of therapies to treat neurodegenerative diseases. The company's product pipeline includes a small molecule inhibitor of RIP1 kinase to treat Alzheimer's and ALS by regulating inflammatory signaling and affecting glial dysfunction in the brain. Also, provides an LRRK2 inhibitor to treat Parkinson's disease.
Key facts about Denali Therapeutics
- Founded Year: 2015
- Location: San Francisco (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2023
- Stage: Public
- Total Funding till date: $347M
- Employee Count: 603 as on Jul 31, 2026
- Investors: Foresite Capital, Baillie Gifford and 10 Others
- Latest Funding Round: Post IPO, Feb 27, 2024, $*****
- Highlight: Public
Developer of a semiconductor-based DNA synthesis platform. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA which is used in diverse fields of medicine, agriculture, industrial chemicals and data storage. It offers synthetic genes, oligo pools, and NGS target enrichment to support research and innovation
Key facts about Twist Bioscience
- Founded Year: 2013
- Location: San Francisco (United States)
- Annual Revenue: $100M - $500M as on Sep 30, 2025
- Stage: Public
- Total Funding till date: $321M
- Employee Count: 1,304 as on Jul 31, 2026
- Investors: Foresite Capital, Fidelity Investments and 39 Others
- Latest Funding Round: Series F, Apr 02, 2018, $*****
- Highlight: Public
4. GRAIL
Developer of a screening platform for circulating tumor DNA to detect cancer. The company is developing a test called "Galleri" a pan-cancer screening test by measuring circulating nucleic acids in the blood. Its proprietary platform uses the ultra-deep sequencing technique to measure levels of circulating tumor DNA in the patient's blood.
Key facts about GRAIL
- Founded Year: 2016
- Location: Menlo Park (United States)
- Annual Revenue: £10M - £50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $2B
- Employee Count: 1,135 as on Jul 31, 2026
- Investors: Foresite Capital, Gershon Capital and 52 Others
- Latest Funding Round: Post IPO, Jun 25, 2026, $*****
- Highlight: Public
5. Neumora
Developer of precision medicines for neuropsychiatric disorders and neurodegenerative disorders. The company has developed Data Biopsy Signatures and Precision Phenotypes technologies by using a data-driven neuroscience platform to design targeted therapies for brain diseases. The product pipeline includes NMRA-140, NMRA-511, and NMRA-094 for depressive disorders, anxiety, sleep, and neurodegenerative disorders.
Key facts about Neumora
- Founded Year: 2020
- Location: Watertown (United States)
- Stage: Public
- Total Funding till date: $612M
- Employee Count: 105 as on Jul 31, 2026
- Investors: Logos, Mubadala and 19 Others
- Latest Funding Round: Series B, Oct 11, 2022, $*****
- Highlight: Public
Biomatics Capital's Year-on-Year Investment Trends
Biomatics Capital has invested in 19 companies over the last 10 years, with an average of 1 new investment annually in the last 10 years. Its most recent first time investment was in Thrive Earlier Detection and most recent follow-on round was in Encodia.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 |
2021 | 0 | 2 | 2 |
2020 | 0 | 2 | 2 |
2019 | 3 | 5 | 8 |
2018 | 6 | 0 | 6 |
2017 | 4 | 1 | 5 |
Biomatics Capital's Investments by Stage
Biomatics Capital has made 8 investments in Series A stage with an average round size of $47.3M, 2 investments in Series B stage with an average round size of $44.3M, 2 investments in Series C stage with an average round size of $25M, 1 investment in Seed stage and 1 investment in Series E stage with an average round size of $27M.Stage of entry | No. of Investments |
|---|---|
Series A | 8 |
Series B | 2 |
Series C | 2 |
Seed | 1 |
Series E | 1 |
Note: We have considered here, only first round of investments
Biomatics Capital's Investments by Sector
Biomatics Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Vertical SaaS. Notably, it has invested in 19 Enterprise (B2B) companies, 19 Tech companies, 4 Software companies and at least 3 companies focusing on Saas.Sector | No. of Investments |
|---|---|
Life Sciences | 13 |
High Tech | 8 |
Enterprise Applications | 3 |
HealthTech | 3 |
Vertical SaaS | 2 |
Others | 1 |
Note: We have considered here, only first round of investments
Biomatics Capital's Investments by Geography
Biomatics Capital has made most investments in United States (13), followed by China where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 13 |
China | 1 |
Note: We have considered here, only first round of investments
Biomatics Capital's recent investments
Biomatics Capital has not made any investment in 2026 so far.Here are the most recent investments by Biomatics Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 27, 2021 | United States | Series C | 7103 | [+7] | |
Jan 19, 2021 | United States | Series B | 8701 | [+10] | |
Jun 23, 2020 | United States | Series A | 6180 | [+7] | |
Jun 11, 2020 | United States | Series A | 8717 | [+4] | |
Dec 10, 2019 | United States | Series C | 1714 | [+5] |
Unicorns in Biomatics Capital's Portfolio
Biomatics Capital has 1 unicorn in its portfolio - Aledade. The most recent unicorn in their portfolio is Aledade which became a unicorn in 2021, 4 years after Biomatics Capital first invested in it.Here is a list of unicorns in Biomatics Capital's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
73 | Provider of primary care physician platform to deliver care for patients | 2014 | Bethesda | Series F | qgvhbvf |
IPOs and Publicly Listed companies in Biomatics Capital's Portfolio
6 of Biomatics Capital's portfolio companies have become public. GRAIL got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2024 and Neumora got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $2.58B.Here are Biomatics Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 25, 2024 | - | - | 6272 | |
Sep 15, 2023 | - | - | 8352 | |
Apr 05, 2021 | Jul 12, 2018 | Series A | 4846 | |
Oct 31, 2018 | Jun 14, 2017 | Series E | 4760 | |
Dec 08, 2017 | - | - | 5531 |
Acquired companies in Biomatics Capital's Portfolio
5 companies from Biomatics Capital's portfolio have been acquired. The most recent acquisition was Verve in Jun 2025 by Lilly for $*****.Here are Biomatics Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 17, 2025 | May 07, 2019 | Series A | 8935 | |
Jul 20, 2021 | Jul 30, 2018 | Series B | 2008 | |
Feb 23, 2021 | Apr 25, 2019 | Series A | 2718 | |
Oct 27, 2020 | May 30, 2019 | Series A | 5992 | |
Jul 29, 2019 | - | - | 4164 |
_1557388532154.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of Biomatics Capital
Biomatics Capital has a team of 2 members including 2 Partners located in United States. Biomatics Capital's team does not sit on the board of any company as of now.Co-investors of Biomatics Capital
Over the past 10 years, 166 investors have co-invested in Biomatics Capital's portfolio companies. This includes funds and angels.
- Invested before Biomatics Capital: Arch Venture Partners, Venrock and 33 others have invested in rounds before Biomatics Capital. There are 3 companies where Arch Venture Partners has invested before Biomatics Capital and 1 company where Venrock has invested before Biomatics Capital.
- Top Co-investors of Biomatics Capital: 42 investors entered a company along with Biomatics Capital. These include investors like Arch Venture Partners (5 companies).
- Invested after Biomatics Capital: A total of 89 investors have invested in Biomatics Capital's portfolio after their investments. Top Investors include Polaris Partners (2 companies), Lux Capital (2 companies) and Casdin Capital (2 companies).
Recent News related to Biomatics Capital
•
Encodia Closes $75M Series C Financing Led by Northpond Ventures and Deerfield ManagementNewswire•Jan 27, 2021•Encodia, Northpond Ventures, Deerfield, Google Ventures and 7 others
•
Crispr Heart Disease Start-Up Raises New $63MTechnology News and Literature•Jun 11, 2020•Verve, Google Ventures, Arch Venture Partners, F-Prime Capital and 4 others
•
Omniome Raises $60M in Series C FinancingFinSMEs•Jan 09, 2020•Omniome, Arch Venture Partners, Decheng Capital, Domain Associates and 3 others
•
AiCure Raises $24.5M in Series C FundingFinSMEs•Nov 07, 2019•AiCure, Palisades Growth Capital, Asahi Kasei, Accelmed and 11 others
•
Engineered Organ Transplant Company Raises New FundsTechnology News and Literature•Nov 07, 2019•eGenesis, Fresenius Medical Care, Arch Venture Partners, Biomatics Capital and 5 others
•
eGenesis Raises $100M in Series B FinancingFinSMEs•Nov 07, 2019•eGenesis, Fresenius Medical Care, Leaps by Bayer, Wellington Partners Venture Capital and 5 others
•
BlackThorn Therapeutics Closes $76 Million Series B to Advance Targeted Therapeutics for Mental HealthBusiness Wire•Jun 13, 2019•Blackthorn Therapeutics, Polaris Partners, Scripps Research, Premier Partners and 8 others
•
•
Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GVBusiness Wire•May 07, 2019•Verve, Google Ventures, Beam Therapeutics, Arch Venture Partners and 3 others
•
Aledade advances with $56mGlobal Corporate Venturing•Jan 22, 2019•Aledade, Venrock, Biomatics Capital
